Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open Label, Multi-center Study of EP2101 Therapeutic Vaccine in Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer (NSCLC)

NCT00104780 is registered in ClinicalTrials.gov with Epimmune as lead sponsor.

NCT NCT00104780
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00104780 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open Label, Multi-center Study of EP2101 Therapeutic Vaccine in Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Lead sponsor
Epimmune
Phase
Phase 2
Overall status
Unknown status
Start date
December 31, 2004
Completion date
Not reported
Enrollment
Not reported
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer